The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

Former Wisconsin Rep. Mike Gallagher joined 'America's Newsroom' to discuss Trump's tariff threat against China and his ...

Shares of Eli Lilly & Co. LLY inched 0.91% higher to $795.35 Friday, on what proved to be an all-around favorable trading ...

After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.